During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier ...

Dana-Farber Cancer Institute researchers will present key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

The mother of a seven-year-old with a life-threatening blood disorder says despite treatments being the same as cancer, they ...

New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is poised to reach US$ 22.2 billion by 2032, with a CAGR of 30% during the forecast period from 2024 to 2032 ...

Our Lady of the Lake Cancer Institute is celebrating after successfully completing a bone marrow transplant so rare it has ...

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...